Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

23andMe Holding Co. - Common Stock (NQ:ME)

0.6063 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 23andMe Holding Co. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies 
From 23andMe, Inc.
Via GlobeNewswire
News headline image
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
From 23andMe, Inc.
Via GlobeNewswire
News headline image
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
From 23andMe, Inc.
Via GlobeNewswire
News headline image
23andMe Reports FY2024 First Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
News headline image
23andMe to Report FY2024 First Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
News headline image
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
From 23andMe, Inc.
Via GlobeNewswire
News headline image
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
With millions of Americans experiencing mental health symptoms, 23andMe+ members now have exclusive access to four mental health reports to help determine their genetic likelihood of having one of... 
From 23andMe, Inc.
Via GlobeNewswire
News headline image
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
From 23andMe, Inc.
Via GlobeNewswire
News headline image
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
From 23andMe, Inc.
Via GlobeNewswire
News headline image
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe Releases New Report Revealing Likelihood of Developing Lupus
23andMe+ members can now gain insights on the chronic autoimmune condition 
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategy 
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers 
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented 
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and... 
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe to Present at Upcoming Investor Conferences
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe Reports FY2023 Third Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe to Report FY2023 Third Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season
From 23andMe Holding Co.
Via GlobeNewswire
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes. 
Via TheNewswire.com
News headline image
23andMe Reports FY2023 Second Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
The presentation outlines plans for the expansion phase of the study (part B), including the specific tumor indications where 23ME-00610 will be tested for anticancer activity 
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication
FDA 510(k) clearance allows 23andMe to report genetics associated with processing of certain statins, provides interpretive drug information for simvastatin, and removes the requirement for... 
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe to Report FY2023 Second Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe to Present at Upcoming Investor Conferences
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting
Poster to provide details on study design and expansion phase for ongoing Phase 1 study in patients with advanced solid malignancies 
From 23andMe Holding Co.
Via GlobeNewswire
News headline image
23andMe to Report FY2023 First Quarter Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.